Most Common Intra-Abdominal Solid Tumor in Children
The most common intra-abdominal solid tumor in children is neuroblastoma (answer b). 1, 2, 3, 4
Epidemiology and Characteristics of Neuroblastoma
- Neuroblastoma is the most common extracranial solid tumor diagnosed in children according to the National Comprehensive Cancer Network (NCCN) Guidelines 1
- It accounts for approximately 29.6% of all intra-abdominal tumors in children, making it the most frequent intra-abdominal solid tumor in the pediatric population 4
- Neuroblastoma is an aggressive embryonal malignancy of neural crest origin with a peak age of onset of 22 months 2
- It represents approximately 11% of all pediatric cancers and 15% of all pediatric cancer deaths 2
- Approximately 70% of neuroblastomas are found in the abdomen, making it the most common site of presentation 3
Clinical Presentation
- The most common clinical presentation is an abdominal mass, though patients may present with various symptoms due to metastatic disease or paraneoplastic syndromes 5
- Common symptoms attributable to hepatic metastasis include abdominal enlargement, abdominal pain, respiratory difficulty due to upward pressure on the diaphragm, and obstruction of the inferior vena cava 6
- Approximately 70% of patients have metastases at the time of diagnosis 3
Comparison with Other Common Intra-Abdominal Tumors
- Wilms' tumor (nephroblastoma) is the second most common intra-abdominal tumor in children, accounting for approximately 25.1% of cases 4
- Other common intra-abdominal tumors in children include:
Age Distribution
- The majority of intra-abdominal tumors (77.2%) occur in children under 5 years of age 4
- Neuroblastoma specifically has a peak incidence in infancy and early childhood 2
- In children with neuroblastoma, survival is best in those under one year of age 3
Treatment Considerations
- Current treatment protocols for neuroblastoma include high-dose chemotherapy with autologous stem cell transplantation, radiation, and surgery 2
- Surgical removal of the tumor is still the primary therapy, with radiation offering significant benefit in patients with stage III disease 3
- Despite advances in treatment, long-term survival rates (>5 years) remain below 50% for high-risk patients 2